• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Patient Case #2: Inflammation management in a 73-year-old patient with routine cataract surgery with MIGS


Denise Visco, MD, MBA, reviews inflammation management in a 73-year-old patient with routine cataract surgery with microinvasive glaucoma surgery (MIGS).

Denise Visco, MD, MBA: Our second case discussion was the 73-year-old also presenting for routine cataract surgery. However, they also have primary open-angle glaucoma, and our candidate for [microinvasive] glaucoma surgery with their cataract surgery. Unfortunately, they also have epiretinal membranes, so vitreomacular traction is an issue for them. Small pupil dilating approximately to 4.5 mm to 5 mm. This patient also wants a toric lens for uncorrected distance vision. The cylinder correction is approximately 2 diopters against the rule. The initial impression of this case with our group had many challenges. We’re concerned with the vitreomacular traction that the patient is a high risk for CME [cystoid macular edema], we know we’re going to have additional manipulation in the eye with potentially a small pupil also having to perform the MIGS [microinvasive glaucoma surgery] procedure. And, the expectation for this patient with wanting a premium procedure is also elevated. We have a heightened challenge here in delivering a great experience for this individual. The most appropriate anti-inflammatory regimen for eyes at risk for CME, as agreed by the group, [is] that patients should be getting their drops 2 to 3 days preoperatively and nonsteroidals as part of that regimen. And a significant portion of the group also felt that topical steroids were appropriate for this patient.


Related Videos
Vance Thompson, MD
© 2024 MJH Life Sciences

All rights reserved.